or anastomotic procedures (range 0 to 8). There were 35 patients with bulbar strictures (53.8%), 15 with penobulbar (23.1%), 10 with penile (15.4%), 4 with membranous (6,2%) and 1 had simultaneously a bulbar and a penile stricture (1.5%) respectively. Prior to the operation a small buccal mucosa biopsy of 0.5cm³ was harvested in local anesthesia. Cells were isolated therefrom and cultivated in an external laboratory through tissue engineering, manufacturing within three weeks to a 3x4 cm large mucous membrane with autologous patient's cells. The operative technique was performed in 56 cases in ventral onlay technique (86.2%), in 5 cases in dorsal inlay technique (7.7%) and in 4 cases combined (6.1%).
INTRODUCTION AND OBJECTIVES: Peno-bulbar urethral stricture disease affects around 0.5% of men. Initial treatment is typically urethrotomy, widening the narrowed area internally by incision using an endoscope-mounted blade. Recurrence within four years will occur in about half of the subjects. Options for further treatment are repeat urethrotomy or reconstruction of the urethra by open urethroplasty. The OPEN Trial sought to estimate the relative benefits of these two interventions.
METHODS: A 24-month trial randomly assigned men from 38 UK NHS hospitals between 27/02/2013 and 23/12/2015 to open urethroplasty or endoscopic urethrotomy 1:1 by a remote system with permuted blocks of variable length. Trial staff recording outcomes were masked to allocation, whilst participants, clinicians and local research staff were not masked. Primary outcome was the area under the curve (AUC) of repeated measurements of a previously validated Patient Reported Outcome Measure (PROM) voiding symptom score. Participants who completed at least three scores: one prior to intervention, one in the first year of follow-up and one during the second year of follow-up were included in the primary complete-case intention to treat analysis. The main secondary outcome was need for re-intervention. ISRCTN: 98009168.
RESULTS: The primary analysis included 69 (63%) of those allocated to urethroplasty and 90 (81%) of those allocated to urethrotomy. The mean (SD) AUC of voiding score at 24-months on a scale from 0 (no symptoms) to 24 (worst symptoms) was 7.4 (3.8) in the urethroplasty group and 7.8 (4.2) in the urethrotomy group, a mean (95% CI) difference of -0.36 (-1.74 to 1.02). Fifteen (16%) men in the urethroplasty group required a re-intervention compared to 29 (28%) of men allocated to urethrotomy. The hazard ratio for time until first re-intervention (95% CI) was 0.52 (0.31 to 0.89).
CONCLUSIONS: In men with recurrent peno-bulbar urethral stricture both urethroplasty and urethrotomy provided effective control of voiding symptoms. The benefit lasted longer, and the need for reintervention lower in those allocated to urethroplasty. Urethral strictures are most commonly treated via minimally invasive techniques such as dilation or direct vision internal urethrotomy (DVIU); but in men who have undergone more than 1 prior treatment, recurrence rates with repeat dilation or DVIU are over 50%, with an average time to recurrence of 3 months . A novel drug coated balloon for urethral dilation (Optilumeä DCB) was designed to mechanically dilate a stricture while delivering paclitaxel, an anti-proliferative drug intended to reduce the rate of stricture recurrence. The ROBUST I study is a multi-center, prospective, non-randomized trial designed to determine the safety and efficacy of the Optilumeä DCB.
Source of
METHODS: Materials & Methods: Men with bulbar urethral strictures 2cm with 1-3 prior endoscopic treatments were enrolled at 4 study sites in the Dominican Republic and Panama following Ethics Committee approvals. The Optilumeä DCB was inflated under cystoscopic visualization and placement confirmed via fluoroscopy. Subjects were evaluated at 2-5 days, 14 days, 3, 6 and 12 months post-treatment. Primary efficacy endpoint was improvement in IPSS and primary safety endpoint was serious complications through 3 months. Secondary endpoints included anatomic success, defined as the urethral lumen caliber !14F based on ability to pass a flexible cystoscope or a 14F catheter and change in uroflowmetry.
RESULTS: Results: Fifty-three subjects were enrolled, and all successfully treated. Average subject age was 51 years (range 22-81). Stricture etiology was traumatic (51%), iatrogenic (45%) and idiopathic (4%). Average number of prior treatments was 1.25 per subject (range 1-4). Prior treatments included rigid dilation and DVIU, however most subjects were on a "dilation program" or selfcatheterization at home. Self-catheterizations were not counted in the number of prior treatments. There were no serious or unexpected device related adverse events.. Overall anatomic success rate at 12 months was 75% (35/47). The 12 failures were composed of 5 retreatments, 4 who failed the urethral lumen test; 3 exited the study for symptoms of recurrence without retreatment or failing the urethral lumen test and were considered failures. Mean IPSS decreased from 25.2AE4.5 (baseline) to 4.9AE5.6 (p<0.001) in 42 men with 12-month data. Mean peak urinary flow (Qmax) increased from 5.0AE2.6 ml/sec (baseline) to 19.5AE9.9 (p<0.001) ml/sec, again in 42 men at 12 months. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e389 CONCLUSIONS: One-year data indicates the Optilumeä DCB treatment is safe and the device produces urethra luminal gain that achieves significant clinical results with meaningful increased Qmax and decreased IPSS.
Source of Funding: Urotronic

PD22-07 ANALYSIS OF PROGRESSIVE LUMENAL EXPANSION ON URETHRAL MICROPERFUSION USING LASER DOPPLER FLOWMETRY IN NEW ZEALAND WHITE MALE RABBITS
Teja Maruvada*, Gregory Joice, Chanya Elakkad, Sarah Beck, E. James Wright, Baltimore, MD INTRODUCTION AND OBJECTIVES: Male urethral stricture disease (USD) is a relatively common condition often requiring multiple endoscopic and open procedures as treatment. Repeat urethral catheterization is a risk factor for USD likely resulting from focal urethral ischemia leading to scar formation but this process is not well understood. We sought to better understand the impact of urethral expansion on tissue microperfusion using a rabbit model. METHODS: 12 NZ white male rabbits were anesthetized and their urethras wereserially expanded using pulmonary CRE balloons (Boston Scientific), which expand to 24/27/30/33 Fr. Concentration and velocity of red blood cells are recorded using a 4 Fr endoscopic sideviewing laser Doppler flowmetry (LDF) probe (Moor Instruments). To assess the impact of expansion time on microperfusion, the balloon was expanded to 30 Fr and LDF measurements were continuously recorded for 30 minutes. Rabbits were euthanized at 0 or 1 week and their urethras harvested and stained for hematoxylin and eosin (H&E) to study the acute and chronic effects of urethral expansion.
RESULTS: Increasing urethral expansion was shown to have an inverse linear relationship tissue microperfusion. Tissue microperfusion was decreased by 74% at 33 Fr expansion compared to 24 Fr (34.30 vs. 107.9 perfusion units (PU), p <0.05). Over time, tissue perfusion increased slightly from nadir of 42.7 PU to peak of 52.4 PU before stabilizing at an expansion on 30 Fr. However, perfusion did not reach normal values at any time period tested. On H&E staining, there was evidence of acute inflammation at week 0 that was no longer present after 1 week. We did not see any evidence of scar formation over this short time period.
CONCLUSIONS: Increasing urethral expansion diameter and duration leads to decreased tissue microperfusion. There is evidence of acute inflammation initially that resolves after 1 week although no scar formation is noted over this time period. Future studies will assess for scar formation with longer expansion times and further time points. Limited evidence exists to guide procedure-specific opioid prescribing best practices and non-opioid based care pathways. We sought to evaluate postoperative opioid requirements and evaluate efficacy of a standardized perioperative pain management pathway for men undergoing anterior urethroplasty.
METHODS: Between August 2017 and October 2018, we prospectively evaluated consecutive men undergoing outpatient urethroplasty by a single surgeon. Standardized perioperative pain pathways were implemented based on urethroplasty location (penile vs. bulbar) and on need for buccal mucosa graft (Figure 1) . Postoperative opioid usage, amount of unused opioid, pain scores (Likert 0 best to 10 worst), and patient satisfaction with pain management (Likert 6 very satisfied to 1 very dissatisfied) were evaluated.
RESULTS: Data was obtained in 46 of 57 consecutive outpatient urethroplasties at a median 14 days after surgery. Median age was 52 years (range 18-77) and postoperative 72 hour pain score was 3 (range 0-8). A total of 7 (15%) patients reported narcotic use within 7 days before surgery. The median number of 5 mg oxycodone tablets used after urethroplasty was 3.5 (range 0-42); 36 of 46 (78%) men used 5 tablets or less. Excess narcotic was prescribed to 38 of 46 (83%) with a median 14 unused tablets (range 5-27) per patient. Postoperative narcotic usage did not differ by age, urethroplasty location, or use of buccal mucosa graft, but was significantly greater among patients that reported preoperative narcotic usage (median 15 vs. 3 tabs; p[0.0008). Men without preoperative narcotic usage rarely required > 5 tablets relative to those using narcotics preoperatively (13% vs. 71%; p[0.003). Overall, 93% (n[43) reported satisfaction (Likert score 5 or 6) with the postoperative pain management strategy.
CONCLUSIONS: In combination with the defined non-opioid care pathway, 5 tablets of 5 mg oxycodone provides satisfactory pain control following anterior urethroplasty in patients without preoperative opioid use, while limiting overprescribing.
